Maryam Masoumi Shahrbabak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maryam Masoumi Shahrbabak has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Faridadin Ebrahimi Meimand
Department of Surgery, Minimally Invasive Surgery Research Center, Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
2 shared publicationsMahdi Khatuni
Department of Pulmonology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publicationMasoumeh Mirzamoradi
Department of Gynecology and Obstetrics, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publicationNayereh Rahmati
Department of Gynecology and Obstetrics, Mahdiyeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publicationParichehr Pooransari
Department of Gynecology and Obstetrics, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publicationSamaneh Omidi
Department of Gynecology and Obstetrics, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 5 June 2023
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (7) , 3709-3717
Remdesivir in pregnant women with moderate to severe coronavirus disease 2019 (COVID-19): a retrospective cohort study
Data on the efficacy of remdesivir in Coronavirus Disease 2019 (COVID-19) are limited in pregnant patients since they have been excluded from clinical trials. We aimed to investigate some clinical outcomes following remdesivir administration in pregnancy. This was a retrospective cohort study conducted on pregnant women with moderate to severe COVID-19. The enrolled patients were divided into two groups with and without remdesivir treatment. The primary outcomes of this study were the length of hospital and intensive care unit stay; respiratory parameters of hospital day 7 including respiratory rate, oxygen saturation, and mode of oxygen support; discharge until days 7 and 14, and need for home oxygen therapy. Secondary outcomes included some maternal and neonatal consequences. Eighty-one pregnant women (57 in the remdesivir group and 24 in the non-remdesivir group) were included. The two study groups were comparable according to the baseline demographic and clinical characteristics. Of the respiratory outcomes, remdesivir was significantly associated with a reduced length of hospital stay (p = 0.021) and also with a lower level of oxygen requirement in patients on low-flow oxygen [odds ratio (OR) 3.669]. Among the maternal consequences, no patients in the remdesivir group developed preeclampsia but three patients (12.5%) experienced this complication in the non-remdesivir group (p = 0.024). Furthermore, in patients with moderate COVID-19, the percentage of emergency termination was significantly lower in remdesivir group (OR 2.46). Our results demonstrated some probable benefits of remdesivir in respiratory and also maternal outcomes. Further investigations with a larger sample size should confirm these results.
- 5 June 2023
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (7) , 3709-3717
Open AccessRemdesivir in pregnant women with moderate to severe coronavirus disease 2019 (COVID-19): a retrospective cohort study
Data on the efficacy of remdesivir in Coronavirus Disease 2019 (COVID-19) are limited in pregnant patients since they have been excluded from clinical trials. We aimed to investigate some clinical outcomes following remdesivir administration in pregnancy. This was a retrospective cohort study conducted on pregnant women with moderate to severe COVID-19. The enrolled patients were divided into two groups with and without remdesivir treatment. The primary outcomes of this study were the length of hospital and intensive care unit stay; respiratory parameters of hospital day 7 including respiratory rate, oxygen saturation, and mode of oxygen support; discharge until days 7 and 14, and need for home oxygen therapy. Secondary outcomes included some maternal and neonatal consequences. Eighty-one pregnant women (57 in the remdesivir group and 24 in the non-remdesivir group) were included. The two study groups were comparable according to the baseline demographic and clinical characteristics. Of the respiratory outcomes, remdesivir was significantly associated with a reduced length of hospital stay (p = 0.021) and also with a lower level of oxygen requirement in patients on low-flow oxygen [odds ratio (OR) 3.669]. Among the maternal consequences, no patients in the remdesivir group developed preeclampsia but three patients (12.5%) experienced this complication in the non-remdesivir group (p = 0.024). Furthermore, in patients with moderate COVID-19, the percentage of emergency termination was significantly lower in remdesivir group (OR 2.46). Our results demonstrated some probable benefits of remdesivir in respiratory and also maternal outcomes. Further investigations with a larger sample size should confirm these results.
- Open Access
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2021 (5) , rjab130
A rare case of Mayer-Rokitansky-Küster-Hauser syndrome with right ovarian torsion and hypoplasia of the left adnexa
The Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is a congenital disorder caused by the abnormal absence of paramesonephric ducts. The main characteristics of this syndrome include hypoplasia or aplasia of the uterus, absence of the cervix and upper part of vagina. Otherwise, ovaries and fallopian tubes have normal functions. A 9-year-old girl presented to the emergency department by acute abdominal pain. Based on a high probable diagnosis of ovarian torsion, surgical exploration was accomplished demonstrating rudimentary or aplastic uterus, hypoplasia of the left adnexa and torsion of the right ovary. In consideration of MRKH syndrome, further assessments were done and the diagnosis was confirmed. As this syndrome is rare and there is a probability of ovarian torsion caused by malformation of the ovarian ligament, physicians should be aware of this syndrome to diagnose it earlier and preserve the ovarian tissue.
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2021 (5) , rjab130
Open AccessA rare case of Mayer-Rokitansky-Küster-Hauser syndrome with right ovarian torsion and hypoplasia of the left adnexa
The Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is a congenital disorder caused by the abnormal absence of paramesonephric ducts. The main characteristics of this syndrome include hypoplasia or aplasia of the uterus, absence of the cervix and upper part of vagina. Otherwise, ovaries and fallopian tubes have normal functions. A 9-year-old girl presented to the emergency department by acute abdominal pain. Based on a high probable diagnosis of ovarian torsion, surgical exploration was accomplished demonstrating rudimentary or aplastic uterus, hypoplasia of the left adnexa and torsion of the right ovary. In consideration of MRKH syndrome, further assessments were done and the diagnosis was confirmed. As this syndrome is rare and there is a probability of ovarian torsion caused by malformation of the ovarian ligament, physicians should be aware of this syndrome to diagnose it earlier and preserve the ovarian tissue.